It is. But that doesn't change the fundamentals of the company...

It is. But that doesn't change the fundamentals of the company and its clinical pipeline/current trials/results/partnerships/potential. It is very interesting the market has allowed the sp to drop back to these levels.. For me it's another opportunity to buy at the levels where I missed an entry last year. I'm quite confident that things will pickup and these prices will be a distant memory.
We all know that investments in biotech can be volatile, high risk high reward - And that trend reversals can come quickly. Risk to reward ratio seems to be in our favour at these prices with the upcoming year.

Only time will tell.